Briacell Therapeutics Corp has seen a notable uptick in its stock price following a significant partnership announcement.
In the latest trading session, Briacell Therapeutics Corp (BCT.TO) experienced a robust gain of 4.52%, closing at CA$4.62. This rise is attributed to the company's recent collaboration with Uneedle, which is set to improve the administration of its lead cancer immunotherapy, Bria-IMT.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$45.76M
52W high
$20.40
52W low
$3.68
1W change
-4.50%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 292.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+292.9% Upside
Current Price
C$5.09
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
60.0%
Annualized
90-Day Vol
87.6%
Annualized
Trend (90d)
-0.8%
Annualized drift
90d Mean
C$5.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.09 | C$4.13 โ C$6.25 |
| 60 trading days | C$5.08 | C$3.79 โ C$6.81 |
| 90 trading days | C$5.08 | C$3.55 โ C$7.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Briacell's partnership with Uneedle as a potential catalyst for future growth, especially in light of its ongoing Phase 3 clinical trials.
Briacell's Market Cap Reaches CA$38.45 Million
With a market cap of CA$38.45 million, Briacell is still in the early stages of its growth trajectory, making it a speculative investment in the biotech sector.
Bull case
The partnership with Uneedle aims to simplify the delivery of Bria-IMT, which could lead to better patient outcomes and quicker regulatory approval. This might position Briacell favorably in the competitive biotech landscape.
Bear case
Despite the positive news, investors should remain cautious. The success of the partnership and clinical trials depends on regulatory approvals, which can be unpredictable.
Partnership with Uneedle
Briacell's recent Memorandum of Understanding with Uneedle is a strategic move to use microneedle technology for administering Bria-IMT. This innovative approach is expected to improve patient experience and streamline the treatment process, potentially making a significant impact in the ongoing Phase 3 trials.
Market Reaction
The market reacted positively to the news, showing investor confidence in Briacell's immunotherapy potential. The 4.52% increase in stock price indicates a favorable outlook among investors, especially as the company advances its pivotal Phase 3 study for advanced metastatic breast cancer.
Looking Ahead
As Briacell continues to develop its pipeline and pursue regulatory approvals, investors should watch for upcoming announcements and trial results. The partnership with Uneedle could be crucial in determining the success of Bria-IMT and the company's future growth.
Advertisement
